Quantitative whole body planar imaging was performed to estimate radiation absorbed doses using OLINDA/EXM software. SPECT imaging of the thorax was performed to evaluate Forskolin order tumor uptake. The pharmacokinetics of elimination from the blood and plasma were determined over 72 h.
Results: There were no acute adverse reactions from In-111-DTPA-trastuzumab Fab fragments and no changes in hematological or biochemical indices were found
over a 3 month period. In-111-DTPA-trastuzumab Fab fragments exhibited a biphasic elimination from the blood and plasma with t(1/2)alpha = 11.9 h and 7.5 h, respectively, and t(1/2)beta = 26.6 and 20.7 h, respectively. The radiopharmaceutical accumulated in the liver, spleen and kidneys. SPECT imaging did not reveal tumor in any patient. The mean effective dose was 0.146 mSv/MBq (10.8 mSv for 74 MBq). Counts in excised tumors were low but were higher than in margins. Margins in two patients harboured tumor but this was not correlated with counts obtained using the gamma-probes. Surgical cavity counts were high and likely due to detection of gamma-photons outside the surgical field.
Conclusion: We conclude that it was not feasible, at least at the administered amount of radioactivity used in this study, to reliably detect the margins of disease in patients with in situ or invasive ductal carcinoma intraoperatively using a hand-held gamma-probe and In-111-DTPA-trastuzumab
HDAC inhibitor Fab fragments due to low IPI-549 nmr uptake in the tumor and involved margins. (C) 2013 Elsevier Inc. All rights reserved.”
“Antidepressants are highly prescribed in youth although most products have not been approved for
use in this population. Furthermore, regulatory warnings have led to changes in antidepressant use that might have differed across various countries. Our study aimed at determining factors associated with antidepressant prescribing practices and at assessing trends in use from 1997 to 2005 in Quebec youth. A retrospective cohort study was conducted through claims databases of the Quebec public health care program (RAMQ). The study included 5094 children (age 2-14) and 11,121 adolescents (age 15-19) who were incident users of antidepressant between 1997 and 2005. The characteristics of users and prescribers were the main independent variables.Tricyclics were the most frequently dispensed products among children (50.9%) and selective serotonin reuptake inhibitors among adolescents (58.8%). Selection of an antidepressant class was associated with patient characteristics and with prescriber specialty. The number of antidepressant users increased from 1997 until 2001 then decreased thereafter.The selection of an antidepressant class was associated with clinical and non-clinical characteristics. Although antidepressant use decreased after regulatory warnings, there appears to be a care gap between the evidence generated by efficacy studies and the products prescribed in a real-life setting. (C) 2010 Elsevier Ireland Ltd.